Interoception refers to the process by which the nervous system senses, interprets, and integrates signals originating from within the body, providing a moment-by-moment mapping of the body's internal landscape across conscious and unconscious levels. Interoceptive signaling has been considered a component process of reflexes, urges, feelings, drives, adaptive responses, and cognitive and emotional experiences, highlighting its contributions to the maintenance of homeostatic functioning, body regulation, and survival. Dysfunction of interoception is increasingly recognized as an important component of different mental health conditions, including anxiety disorders, mood disorders, eating disorders, addictive disorders, and somatic symptom disorders. However, a number of conceptual and methodological challenges have made it difficult for interoceptive constructs to be broadly applied in mental health research and treatment settings. In November 2016, the Laureate Institute for Brain Research organized the first Interoception Summit, a gathering of interoception experts from around the world, with the goal of accelerating progress in understanding the role of interoception in mental health. The discussions at the meeting were organized around four themes: interoceptive assessment, interoceptive integration, interoceptive psychopathology, and the generation of a roadmap that could serve as a guide for future endeavors. This review article presents an overview of the emerging consensus generated by the meeting.
|Original language||English (US)|
|Number of pages||13|
|Journal||Biological Psychiatry: Cognitive Neuroscience and Neuroimaging|
|State||Published - Jun 2018|
Bibliographical noteFunding Information:
AEM reports the following disclosures: research/grant: National Institutes of Health (NIH) Grant No. 1U01EB021952-01; scientific advisory board: Anxiety and Depression Association of America. AvL reports the following disclosures: research/grants: Research Fund KU Leuven, Belgium (Grant Nos. STRT/13/002 and DBOF/14/021), an infrastructure grant from the Herculesstichting, Belgium (Grant No. AKUL/13/07), “Asthenes” long-term structural funding Methusalem grant (Grant No. METH/15/011) by the Flemish Government, Belgium. CBN reports the following disclosures: research/grant: NIH, Stanley Medical Research Institute; consulting (last 3 years): Xhale, Takeda, Taisho Pharmaceutical, Inc., Prismic Pharmaceuticals, Bracket (Clintara), Total Pain Solutions, Gerson Lehrman Group Healthcare & Biomedical Council, Fortress Biotech, Sunovion Pharmaceuticals, Inc., Sumitomo Dainippon Pharma, Janssen Research & Development, LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., TC MSO, Inc.; stockholder: Xhale, Celgene, Seattle Genetics, Abbvie, OPKO Health, Inc., Bracket Intermediate Holding Corporation, Network Life Sciences, Inc., Antares; scientific advisory boards: American Foundation for Suicide Prevention (AFSP), Brain and Behavior Research Foundation (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]), Xhale, Anxiety and Depression Association of America (ADAA), Skyland Trail, Bracket (Clintara), RiverMend Health, LLC, Laureate Institute for Brain Research, Inc.; board of directors: AFSP, Gratitude America, ADAA; income sources or equity of $10,000 or more: American Psychiatric Publishing, Xhale, Bracket (Clintara), CME Outfitters, Takeda; patents: method and devices for transdermal delivery of lithium (Patent No. US 6,375,990B1), method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (Patent No. US 7,148,027B2). HDC reports the following disclosures: research/grants: European Research Council Horizon 2020 Proof of Concept Grant “HeartRater: Tools for the systematic evaluation of interoceptive ability,” Medical Research Council (UK) MRC Confidence in Concept Grant “Identifying neural, cognitive, and phenomenological markers of auditory verbal hallucinations in borderline personality,” MQ (Mental Health) PsyImpact “Aligning Dimensions of Interoceptive Experience (ADIE) to prevent development of anxiety disorders in autism,” Dr. Mortimer and Theresa Sackler Foundation Sackler Centre for Consciousness Science, University of Sussex, BIAL Foundation Bursary “Microneurography as a tool for consciousness science”; scientific advisory boards: Emteq, Ltd., unpaid governor on board of charity “Reflecting nature in art & science”; board of directors: Codirector of Sackler Centre for Consciousness Science, University of Sussex. KES reports the following disclosures: research/grants: Deutsche Forschungsgemeinschaft, Transregional Collaborative Research Centre, “Ingestive Behaviour: Homeostasis and Reward,” René and Susanne Braginsky Foundation. LPS reports the following disclosures: scientific advisory board: Laureate Institute for Brain Research, Inc. JDF reports the following disclosures: research/grants: NIH Grant Nos. R01MH105662, R21MH110865, and R01HD087712; scientific advisory boards: International Obsessive-Compulsive Disorder Foundation Clinical and Scientific Advisory Board. JLR reports the following disclosures: research/grants: NIH Grant No. R01MD007807 and Oklahoma Center for the Advancement of Science and Technology Grant No. HR15-079. JSF reports the following disclosures: research/grants: NIH/National Institute of General Medical Sciences (NIGMS) Grant No. P20GM121312, Brain and Behavior Research Foundation (formerly NARSAD) Young Investigator Award. MBS reports the following disclosures: scientific advisory board: Laureate Institute for Brain Research, Inc.; editorial board: Depression and Anxiety, Biological Psychiatry. MPP reports the following disclosures: research/grants: the William K. Warren Foundation and NIH Grant No. R01DA016663, NIH/NIGMS Grant No. P20DA027834, and NIH Grant Nos. R01DA027797, R01DA018307, U01DA041089, and 1R01MH101453; consulting (last 3 years): has received royalties for an article about methamphetamine use disorder from UpToDate. OVdB reports the following disclosures: scientific advisory boards: Research Training Group 2271 of the Deutsche Forschungsgemeinschaft on “Expectation maintenance vs. change in the context of expectation violations: Connecting different approaches,” University of Marburg. RDL reports the following disclosures: research/grant: NIH. SSK reports the following disclosures: research/grants: NIH/National Institute of Mental Health Grant No. K23MH112949, NIH/NIGMS Grant No. P20GM121312, William K. Warren Foundation, Brain and Behavior Foundation (formerly NARSAD) Young Investigator Award. WEM reports the following disclosures: research/grants: NCIRE (Veterans Health Research Institute, San Francisco, California), Alzheimer's Association, Mental Insight Foundation, the Pepper Foundation, University of California, San Francisco, Resource Allocation Program. WKS reports the following disclosures: research/grants: NIH Grant No. P20GM121312, Brain and Behavior Foundation (formerly NARSAD) Young Investigator Award. The remaining authors report no biomedical financial interests or potential conflicts of interest.
© 2017 Society of Biological Psychiatry
- Computational psychiatry
- Mental health
- Research Domain Criteria